cerca CERCA
Martedì 28 Novembre 2023
Aggiornato: 17:05
Temi caldi


Liuc presenta STEINBOCC: l’algoritmo che “sveglia” la gara

Una web app come strumento previsionale, a supporto delle centrali d’acquisto per il calcolo realistico del fabbisogno farmaceutico nella gestione degli appalti pubblici. La proposta delle aziende: accordo quadro multi-aggiudicatario per scongiurare le carenze.

comunicato stampa

Scientific Research Report Highlights Medit i700 wireless, Medit i700, and Medit i600 as Top Intraoral Scanners in Dentistry

SEOUL, South Korea and LONG BEACH, Calif., June 6, 2023 /PRNewswire/ -- A recent transnational questionnaire study conducted by the Institute of Digital Dentistry(iDD) has recognized the Medit i700 wireless and Medit i700 as the top two intraoral scanners in dentistry. Furthermore, the study ranked the Medit i600 among the top four scanners. This groundbreaking research involved 1,072 respondents from 109 different countries and spanned over three quarters.

comunicato stampa

Edward W. Marple, A.B. (Harvard), MBA (Virginia), joins Paraza Pharma as Executive Vice-President, Development

MONTREAL, June 5, 2023 /PRNewswire/ -- Paraza Pharma is pleased to announce the appointment of Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) as Executive Vice-President, Development.  Mr. Marple, who has more than 20 years of experience as a senior executive with broad skill sets across clinical development, IP protection, manufacturing, operations, company and product strategy, finance, and commercial partnering/development in the biotechnology and pharmaceutical industry.

comunicato stampa

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

MUMBAI, India and SIENA, Italy, May 30, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) (together with its subsidiaries and/or associated companies, "Sun Pharma") and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen's specialty product, Nidlegy™ (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy™, currently in Phase II...

comunicato stampa

Performance Biofilaments Inc. Announces Start-Up of Nanofibrillated Cellulose Commercial Production

VANCOUVER, BC, May 17, 2023 /PRNewswire/ -- Performance BioFilaments Inc. is pleased to announce the start-up of the world's largest nanofibrillated cellulose (NFC) commercial production plant at Resolute's Forest Products, Kénogami paper mill in Quebec. A daily production capacity of 21 metric tons is now available to supply customers for commercial orders in concrete and mortar, nonwoven, industrial fluid, biocomposite plastic, thin film and mineral consolidation applications. A small dose of t...

comunicato stampa

Datacolor acquires matchmycolor

LAWRENCEVILLE, N.J., May 16, 2023 /PRNewswire/ -- Datacolor AG, a global leader in color management solutions, announces the acquisition of matchmycolor LLC, a technology company specialized in color formulation and communication software. Datacolor consolidates matchmycolor as of January 1, 2023. The costs for the acquisition and the integration will affect the fiscal years 2022/23 and 2023/24. The strategic acquisition strengthens Datacolor's market position and further expands its global indus...

comunicato stampa

Wanhua Chemical Signs Cooperation Deal with French Enterprise to Collaborate on Penglai Industrial Park Seawater Desalination Project

BEIJING, May 15, 2023 /PRNewswire/ -- Wanhua Chemical ("Wanhua" or "the Company"; 600309.SS), along with other representatives from China and France, signed a three-party cooperative agreement recently to collaborate on Wanhua Chemical's Penglai Industrial Park seawater desalination project. The signing ceremony was held in Beijing at the fifth meeting of the Council of China-France Entrepreneurs, an official event for French President Emmanuel Macron's visit to China.

comunicato stampa

Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol. 2023 May 8;16(1):50). This study is the first large Phase I clinical trial of QL1706 in humans, and was led by Prof. Li Zhang and his team at Sun Yat-sen University Cancer Center. The results provide further support for the use of dual immuno...

comunicato stampa

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

PARIS, May 10, 2023/PRNewswire/ -- Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a targeted therapy in two indications: in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy; as well as in monotherapy for the treatment of adult...

comunicato stampa

/C O R R E C T I O N -- Croma-Pharma/

In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the footnote [1] has been updated. The complete, corrected release follows:

comunicato stampa

Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter

VIENNA, May 9, 2023 /PRNewswire/ -- Croma-Pharma GmbH (Croma) today announced its 2022 financial results. 2022 was shaped by strong year-on-year revenue growth of 27% (total reported revenue rose from €95.8 million in 2021 to €121.2 million in 2022) which is believed to be the beginning of a period of rapid revenue growth fuelled by the future launch of new products, international expansion and strong overall market growth. The 2022 results were also driven by the launch of the new product Letybo...

comunicato stampa

Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses

GAITHERSBURG, Md., May 9, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its COVID-Influenza Combination (CIC), stand-alone influenza and high-dose COVID vaccine candidates all showed a reassuring preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators. Additionally, all three ...


whatsapp linkedin twitter youtube facebook instagram
ora in
Prima pagina
Tag più usati
in questa pagina

accesso alle cure


documenti della riforma

eul assists


legislazione farmaceutica ue

novavax's updated protein based covid


platea di pazienti

richieste in audizione al senato

in Evidenza